Sarcopenia - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sarcopenia - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Sarcopenia - Pipeline Review, H1 2016', provides an overview of the Sarcopenia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia
- The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects
- The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sarcopenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sarcopenia Overview 7
Therapeutics Development 8
Pipeline Products for Sarcopenia - Overview 8
Pipeline Products for Sarcopenia - Comparative Analysis 9
Sarcopenia - Therapeutics under Development by Companies 10
Sarcopenia - Therapeutics under Investigation by Universities/Institutes 11
Sarcopenia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Sarcopenia - Products under Development by Companies 14
Sarcopenia - Products under Investigation by Universities/Institutes 15
Sarcopenia - Companies Involved in Therapeutics Development 16
GlaxoSmithKline Plc 16
MYOS Corporation 17
Neurotune AG 18
Novartis AG 19
PolyNovo Limited 20
PsiOxus Therapeutics Limited 21
Regeneron Pharmaceuticals, Inc. 22
Sumitomo Dainippon Pharma Co., Ltd. 23
Sarcopenia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AOD-9604 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ARM-210 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bimagrumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BIO-101 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BIO-103 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DA-4210 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
espindolol - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NEP-28 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NT-1654 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Proteins for Musculoskeletal Disorders - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Recombinant Protein for Sarcopenia - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
S-107 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
trevogrumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Sarcopenia - Recent Pipeline Updates 51
Sarcopenia - Dormant Projects 55
Sarcopenia - Discontinued Products 56
Sarcopenia - Product Development Milestones 57
Featured News & Press Releases 57
Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th 57
Nov 17, 2015: Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob 57
Sep 21, 2015: BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity 57
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 58
Dec 14, 2011: Calzada Announces New Applications For AOD9604 59
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 59
Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia 60
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development for Sarcopenia, H1 2016 8
Number of Products under Development for Sarcopenia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Sarcopenia - Pipeline by GlaxoSmithKline Plc, H1 2016 16
Sarcopenia - Pipeline by MYOS Corporation, H1 2016 17
Sarcopenia - Pipeline by Neurotune AG, H1 2016 18
Sarcopenia - Pipeline by Novartis AG, H1 2016 19
Sarcopenia - Pipeline by PolyNovo Limited, H1 2016 20
Sarcopenia - Pipeline by PsiOxus Therapeutics Limited, H1 2016 21
Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 22
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Sarcopenia Therapeutics - Recent Pipeline Updates, H1 2016 51
Sarcopenia - Dormant Projects, H1 2016 55
Sarcopenia - Discontinued Products, H1 2016 56